FDA Adverse Event Injury Summary report: N

EDWARDS SAPIEN TRANSCATHETER HEART VALVE

MDR report key: 3813606 · Received May 15, 2014

Report

Report Number
2015691-2014-01160
Event Type
Injury
Date Received
May 15, 2014
Date of Event
April 23, 2014
Report Date
April 23, 2014
Manufacturer
EDWARDS LIFESCIENCES
Product Code
NPT
PMA / PMN Number
P110021
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

PER THE INSTRUCTIONS FOR USE, CONDUCTION SYSTEM INJURIES (HEART BLOCK) WHICH MAY REQUIRE A PERMANENT PACEMAKER ARE POTENTIAL ADVERSE EVENTS ASSOCIATED WITH BALLOON AORTIC VALVULOPLASTY, DEPLOYMENT OF THE PROSTHETIC VALVE, AND THE OVERALL TAVR PROCEDURE. ACCORDING TO THE VALVE ACADEMIC RESEARCH CONSORTIUM (VARC) GUIDELINES, THE CLOSE ANATOMICAL RELATIONSHIP BETWEEN THE AORTIC VALVE COMPLEX AND THE BRANCHING ATRIOVENTRICULAR BUNDLE MAY PROVIDE AN EXPLANATION FOR THESE COMPLICATIONS OF THE TAVR PROCEDURE. ACCORDING TO LITERATURE REVIEW, AND AS DOCUMENTED IN A CLINICAL TECHNICAL SUMMARY WRITTEN BY EDWARDS LIFESCIENCES, ATRIOVENTRICULAR CONDUCTION DISTURBANCES AFTER TAVR ARE ASSOCIATED WITH MANY PATIENT RELATED AND PROCEDURAL RELATED FACTORS, INCLUDING PRE-OPERATIVE CO-MORBID STATUS, THE DEGREE AND BULKINESS OF AORTIC VALVE AND ANNULAR CALCIFICATION, INTER-VENTRICULAR SEPTAL THICKNESS, PRE-EXISTING ELECTROCARDIOGRAM ABNORMALITIES, THE DEPTH OF PROSTHESIS IMPLANTATION, AND THE PROFILE OF THE IMPLANTED PROSTHESIS. UNLIKE CONVENTIONAL AVR, WHERE THERE MAY BE LOCALIZED TRAUMA DUE TO DECALCIFICATION OF THE ANNULUS AND/OR SUTURE PLACEMENT IN THE PROXIMITY OF THE AV NODE OR THE BUNDLES, TAVR MAY CAUSE CONDUCTION ABNORMALITIES THROUGH MECHANICAL IMPINGEMENT OF THE CONDUCTION SYSTEM BY THE PROSTHESIS. THE MECHANISMS OF THE DEVELOPMENT OF HEART BLOCK AFTER TAVR ARE WELL DOCUMENTED AND DESCRIBED IN THE LITERATURE. IT IS ALSO DOCUMENTED THAT PRE-EXISTING HEART BLOCK IS COMMON IN PATIENTS UNDERGOING TAVR OR SURGICAL AVR AND ANOTHER 4-6 % WILL DEVELOP POSTOPERATIVE HEART BLOCK, POTENTIALLY REQUIRING A PERMANENT PACEMAKER. IN THIS CASE, IN ADDITION TO PROCEDURAL FACTORS (DEVICE INTERACTION WITH THE CONDUCTION SYSTEM), THE PATIENT¿S CARDIAC PATHOLOGY (E.G. SEVERE AORTIC STENOSIS WITH BULKY CALCIFICATION) MAY HAVE CONTRIBUTED TO THIS EVENT. THE IFU AND TRAINING MANUALS HAVE BEEN REVIEWED AND NO INADEQUACIES HAVE BEEN IDENTIFIED WITH REGARDS TO WARNINGS, CONTRAINDICATIONS, AND THE DIRECTIONS/CONDITIONS FOR THE SUCCESSFUL USE OF THE DEVICE. COMPLAINT HISTORIES FOR ALL REPORTED EVENTS ARE REVIEWED AGAINST TRENDING CONTROL LIMITS ON A (B)(4) BASIS, AND ANY EXCURSIONS ABOVE THE CONTROL LIMITS ARE ASSESSED AND DOCUMENTED AS PART OF THIS (B)(4) REVIEW. NO CORRECTIVE OR PREVENTATIVE ACTIONS ARE REQUIRED AT THIS TIME.

Description of Event or Problem · 1

THE PATIENT WAS REPORTED TO HAVE SEVERE STENOSIS AND SOME AORTIC INSUFFICIENCY. NO BAV WAS PERFORMED PRIOR TO VALVE PLACEMENT. DURING THE ADVANCEMENT OF THE VALVE ACROSS THE NATIVE VALVE, THE NATIVE VALVE WAS NOTED TO BE VERY TIGHT. DURING FINE POSITIONING OF THE 23 MM SAPIEN VALVE, THE PATIENT DEVELOPED COMPLETE HEART BLOCK. THE TEMPORARY PACER WAS STARTED AND THE VALVE WAS DEPLOYED. THE PATIENT RECEIVED A PERMANENT PACEMAKER FOLLOWING THE TAVR PROCEDURE. PER THE REPORTER, THE BUNDLE OF HIS WAS AFFECTED DURING THE PRE-DEPLOYMENT VALVE POSITIONING, RESULTING IN THE COMPLETE HEART BLOCK.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
291107 EDWARDS SAPIEN TRANSCATHETER HEART VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED NPT EDWARDS LIFESCIENCES 9000TFX23 NA

Patients

Seq Age Sex Outcome Treatment
1 72 YR Required Intervention